Interview: Business of Biotech Podcast
Published: Apr 28, 2021

Nevan Charles Elam, JD founded Rezolute Bio ten years ago on the heels of a complex career intersecting law, high tech, and life sciences. On this episode of the Business of Biotech, Elam shares the company's rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies and discusses the company's approach to process development and manufacturing.

Pivots During Pandemic Bring Patient-Centric Options to Rare Disease Patients
Published: Mar 1, 2021

Article: Clinical Leader
Published: Oct 22, 2020

Head of Clinical Operations Erin O'Boyle: Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma's Playbook

Article: International Biopharmaceutical Industry
Published: Jul 28, 2020

Head of Clinical Development Dr. Brian Roberts: Congenital Hyperinsulinism Treatment Gaps and a Potential Solution

Interview: San Francisco Business Times
Published: Jun 11, 2020

CEO Nevan Elam with SF Busines Times' Ron Leuty: How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood disease

Interview: The Rare Daily
Published: Jun 11, 2020

CEO Nevan Elam with Global Genes' Marie Daghlian: Rezolute Gains Rare Pediatric Disease Designation for RZ358 in Congenital Hyperinsulinism

Interview: Empowered Patient Podcast
Published: Feb 3, 2020

CEO Nevan Elam with Karen Jagoda: Developing Therapeutics for Rare Pediatric Diseases 

Nature's BioPharma Dealmakers
Published: Nov 1, 2019

Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 edition